In terms of valuation, Vincerx Pharma Inc’s market capitalization stands at $3.62 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market ...

Vincerx Pharma Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -84.03%. The profit margin, also known as the revenue ratio or gross profit ratio, ...

Leerink Partnrs also issued estimates for Halozyme Therapeutics’ Q2 2025 earnings at $1.04 EPS, Q3 2025 earnings at $1.41 EPS and FY2029 earnings at $8.16 EPS. Get Halozyme Therapeutics alerts: ...

Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report) – Research analysts at Leerink Partnrs issued their Q2 2025 earnings per share estimates for shares of Vir Biotechnology in a report released ...

Leerink notes that Eli Lilly (LLY) lowered its Q4 total revenue guidance by 5% but issued initial 2025 revenue guidance 2% above consensus. Q4 Mounjaro and Zepbound sales were approximately 18% ...

On Monday, Progyny (NASDAQ:PGNY) shares saw a change in their market prospects as Leerink Partners adjusted the company's price target. Analysts at Leerink Partners increased the price target on ...

Op maandag zagen de aandelen van Progyny een verandering in hun marktvooruitzichten toen Leerink Partners het koersdoel van het bedrijf aanpaste. Analisten van Leerink Partners verhoogden het ...

On Monday, Progyny (NASDAQ:PGNY) shares saw a change in their market prospects as Leerink Partners adjusted the company's price target. Analysts at Leerink Partners increased the price target on ...

Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (WBAG:ALGN) from Market Perform to Outperform. There are 1,519 funds or institutions reporting ...

On Monday, Leerink Partners upgraded Align Technology (NASDAQ:ALGN) shares from Market Perform to Outperform and increased the price target to $280 from $235. The firm’s analysts cited an improved ...